Literature DB >> 19130137

Solitary dermal melanoma: beginning or end of the metastatic process?

Chris C Lee1, Mark B Faries, Xing Ye, Donald L Morton.   

Abstract

BACKGROUND: Solitary dermal melanoma (SDM) is confined to the dermal and/or subcutaneous tissue without an epidermal component. It is unclear whether this lesion is a subtype of primary melanoma or distant cutaneous metastasis from an unknown primary. We evaluated our large experience to determine the prognosis and optimal management of SDM.
METHODS: Our melanoma referral center's database of prospectively acquired records was used for identification and clinicopathologic analysis of patients presenting with SDM between 1971 and 2005.
RESULTS: Of 12,817 database patients seen during a 34-year period, 101 (0.8%) had SDM. Of 92 patients free of distant metastasis on initial presentation, 55 (60%) were observed and 37 (40%) underwent surgical nodal staging: regional metastases were identified in 7 (19%). Nodal recurrence occurred in 1 of 30 patients (3.3%) with histopathology-negative nodes compared with 13 of 55 patients (24%) who underwent nodal observation instead of nodal staging. Thus, 21 of 92 patients (23%) had nodal metastasis identified during surgical nodal staging or postoperative nodal observation. At a median follow-up of 68 months, estimated 5-year overall survival rate was 73% for 71 patients with localized disease versus 67% for 21 patients with regional disease (P=0.25) versus 22% for 9 patients with distant disease (P=0.009, regional versus distant disease).
CONCLUSIONS: SDM resembles intermediate-thickness primary cutaneous melanoma with respect to prognostic characteristics and clinical evolution, but its rate of distant metastasis justifies radiographic staging and its high rate of regional node metastasis justifies wide excision and sentinel node biopsy.

Entities:  

Mesh:

Year:  2009        PMID: 19130137      PMCID: PMC2673232          DOI: 10.1245/s10434-008-0272-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  24 in total

Review 1.  Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy.

Authors:  M B Lens; M Dawes; J A Newton-Bishop; T Goodacre
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

Review 2.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

3.  Metastatic malignant melanoma with an unknown primary.

Authors:  D S Reintgen; K S McCarty; B Woodard; E Cox; H F Seigler
Journal:  Surg Gynecol Obstet       Date:  1983-03

4.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer.

Authors:  A E Giuliano; D M Kirgan; J M Guenther; D L Morton
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

5.  Primary dermal melanoma: a distinct subtype of melanoma.

Authors:  Susan M Swetter; Phillip M Ecker; Denise L Johnson; Jeff D Harvell
Journal:  Arch Dermatol       Date:  2004-01

6.  Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?

Authors:  Katharine A Yao; Eddy C Hsueh; Richard Essner; Leland J Foshag; Leslie A Wanek; Donald L Morton
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

7.  Clinical aspects of unknown primary melanoma.

Authors:  A E Giuliano; H S Moseley; D L Morton
Journal:  Ann Surg       Date:  1980-01       Impact factor: 12.969

8.  Cutaneous melanoma: prognosis and treatment results worldwide.

Authors:  C M Balch
Journal:  Semin Surg Oncol       Date:  1992 Nov-Dec

9.  Natural history and selective management of in transit melanoma.

Authors:  J H Wong; L A Cagle; K H Kopald; S G Swisher; D L Morton
Journal:  J Surg Oncol       Date:  1990-07       Impact factor: 3.454

10.  Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.

Authors:  Dennis L Rousseau; Merrick I Ross; Marcella M Johnson; Victor G Prieto; Jeffrey E Lee; Paul F Mansfield; Jeffrey E Gershenwald
Journal:  Ann Surg Oncol       Date:  2003-06       Impact factor: 5.344

View more
  6 in total

1.  Utility of sentinel lymph node biopsy for solitary dermal melanomas.

Authors:  Yinin Hu; Puja Shah; George J Stukenborg; Craig L Slingluff
Journal:  J Surg Oncol       Date:  2015-02-24       Impact factor: 3.454

2.  Paraganglioma-like dermal melanocytic tumor: a case report with particular features.

Authors:  Anca Maria Cimpean; Raluca Ceauşu; Marius Raica
Journal:  Int J Clin Exp Pathol       Date:  2009-11-20

3.  Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy.

Authors:  Matthew P Doepker; Zachary J Thompson; Jennifer N Harb; Jane L Messina; Christopher A Puleo; Kathleen M Egan; Amod A Sarnaik; Ricardo J Gonzalez; Vernon K Sondak; Jonathan S Zager
Journal:  J Surg Oncol       Date:  2015-12-10       Impact factor: 3.454

4.  Primary dermal melanoma in a patient with a history of multiple malignancies: a case report with molecular characterization.

Authors:  Germana Sini; Maria Colombino; Amelia Lissia; Sara Maxia; Marcello Gulino; Panagiotis Paliogiannis; Grazia Palomba; Giuseppe Palmieri; Antonio Cossu; Corrado Rubino
Journal:  Case Rep Dermatol       Date:  2013-07-18

5.  Treatment of Regional Metastatic Melanoma of Unknown Primary Origin.

Authors:  Elke J A H van Beek; Alfons J M Balm; Omgo E Nieweg; Olga Hamming-Vrieze; Peter J F M Lohuis; W Martin C Klop
Journal:  Cancers (Basel)       Date:  2015-08-10       Impact factor: 6.639

Review 6.  Unusual Clinical Presentations of Malignant Melanoma: A Review of Clinical and Histologic Features with Special Emphasis on Dermatoscopic Findings.

Authors:  Raúl Cabrera; Francisca Recule
Journal:  Am J Clin Dermatol       Date:  2018-11       Impact factor: 7.403

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.